SCHEMBL6238046

SCHEMBL6238046

O=c1c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2ccccc2n1CCc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.72
MAPK1 P28482 1/20 0.72
CYP2C9 P11712 3/20 0.60
NR1I2 O75469 1/20 0.60
KDM4E B2RXH2 7/20 0.43
GAA P10253 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 2/20 0.41
RECQL P46063 1/20 0.41
CASP6 P55212 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 2/20 0.41
RCE1 Q9Y256 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6235919 0.95 HSD17B10 (0.68) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6739989 0.90 HSD17B10 (0.74) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6235175 0.89 HSD17B10 (0.65) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6211629 0.88 HSD17B10 (0.72) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL1523007 0.88 MAPK1 (0.58) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6267293 0.87 HSD17B10 (0.68) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL8239358 0.87 HSD17B10 (0.74) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6732624 0.87 HSD17B10 (0.71) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6235373 0.87 HSD17B10 (0.74) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL6208298 0.86 HSD17B10 (0.69) HSD17B10MAPK1CYP2C9NR1I2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
CN-1535151-A Novel anti-infectives ʷ��˿�������ȳ�ķ���޹�˾ 2004-10-06 CN claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 HSD17B10 1428/4885MAPK1 3699/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.